Examples of using Maximum human in English and their translations into Danish
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
Effects in non-clinical studies were generally observed at exposures in excess of the maximum human exposure.
These effects were observed at exposure levels in excess of the maximum human exposure indicating little relevance to clinical use.
The maximum human dose should not exceed 2 units since efficacy and safety for spinal fusion requiring higher doses has not been established.
Cinacalcet was not teratogenic in rabbits when given at a dose of 0.4 times,on an AUC basis, the maximum human dose for secondary HPT 180 mg daily.
The maximum human dose should not exceed 2 vials since efficacy in the treatment on non-unions with gaps requiring higher doses has not been established.
The No Observed Adverse Effect Level(NOAEL)for female fertility was 10 mg/kg/day 20 times the maximum human exposure after dermal application.
Estrous cycles were affected at doses of 1.1 mg/ kg(3 times the maximum human dose) and reproduction parameters were influenced in rats given 3 mg/ kg 9 times the maximum human dose.
The no observed effect level(NOEL) for both the maternal animals andthe F1 generation was 15 mg/ kg/ day one quarter of the maximum human dose of 800 mg.
In preclinical studies in rats anddogs, Renagel at a dose of 10 times the maximum human doses reduced absorption of fat soluble vitamins D, E and K, and folic acid.
Deficits in skeletal ossification were observed in several locations in fetuses of female rats dosed with sevelamer at 8-20 times the maximum human dose of 200 mg/ kg.
In rats a 2-year carcinogenicity study demonstrates at a dose of 100mg/kg/day(125 times the maximum human mg/kg/dose) a statistically significant increase in the incidence of hepatocellular carcinomas in males only.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology orrepeated dose toxicity at 2-fold the maximum human exposure to parecoxib.
At two-fold systemic exposure compared to maximum human therapeutic exposure, there was an increase in post- implantation loss, decrease in the pup birth weights, and reduction in pup survival during the first three days of lactation in rats.
The lowest dose studied represented exposure multiples of 1x for buprenorphine and 5x for naloxone at the maximum human therapeutic dose calculated on a mg/ m² basis.
Changes observed in monkeys at, orin small excess of, the maximum human exposure during repeated dose studies, were all related to the pharmacological effect of Xigris and include beside the expected prolongation of APTT, decreases in haemoglobin, erythrocytes and haematocrit, and increases in reticulocyte count and PT.
However findings were only seen at exposure levels considered being higher than the maximum human exposure, indicating limited relevance to clinical use.
Repeated dose studies indicate that pravastatin may induce varying degrees of hepatotoxicity and myopathy; in general, substantive effects on these tissues were only evident at doses 50 or more times the maximum human mg/kg dose.
Other preclinical effects were observed only at exposures that were sufficiently in excess of the maximum human exposure so that concern for human safety is negligible.
Preclinical effects observed occurred at exposures sufficiently in excess of the maximum human exposure as to indicate little relevance to clinical use, or were due to the pharmacodynamic action(hypoglycaemia) of the compound.
When normalised to body surface area, the exposure to rivastigmine and its metabolites was approximately equivalent to the maximum recommended human dose of 12 mg/ day; however, when compared to the maximum human dose, a multiple of approximately 6-fold was achieved in animals.
Acute toxicity studies employing ioflupane at dosage levels of 0.06 mg/ kg,in excess of 6,500 times the maximum human(70 kg) single dose on a bodyweight basis, failed to reveal any mortality or signs of systemic toxicity in rats or rabbits.
Prolongation of the QTc interval in dogs was observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
In mice, a 2-year carcinogenicity study with pravastatin demonstrates at doses of 250 and 500 mg/kg/day(≥ 310 times the maximum human mg/kg dose), a statistically significant increases in the incidence of hepatocellular carcinomas in males and females, and lung adenomas in females only.
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
These doses represent 2 and 1 times, respectively, the maximum recommended human dose.
The dose of 150 mg/ kg approximately corresponds to the maximum recommended human dose.